Novel integrin receptor antagonists

Details Novel integrin receptor antagonists Novel integrin receptor antagonists

C - Chemistry, Metallurgy

07

D

C07D 403/12 (2006.01) A61K 31/41 (2006.01) A61K 31/435 (2006.01) A61K 31/495 (2006.01) A61K 31/53 (2006.01) A61K 31/535 (2006.01) A61K 31/54 (2006.01) A61K 31/55 (2006.01) A61K 31/675 (2006.01) C07D 401/12 (2006.01) C07D 401/14 (2006.01) C07D 405/14 (2006.01) C07D 409/14 (2006.01) C07D 411/14 (2006.01) C07D 413/14 (2006.01) C07D 417/14 (2006.01) C07D 453/02 (2006.01) C07D 471/04 (2006.01) C07D 473/00 (2006.01) C07D 475/00 (2006.01) C07D 487/04 (2006.01) C07D 513/04 (2006.01) C07D 519/00 (2006.01) C07F 9/655

Patent

CA 2240439

This invention relates to novel heterocycles including 3-[1-[3-(imidazolin-2- ylamino)propyl]indazol-5-ylcarbonylamino]-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the .alpha.v.beta.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiongenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Nouveaux hétérocycles comprenant de l'acide 3-[1-[3-(imidazolin-2-ylamino)propyl]indazol-5-ylcarbonylamino]-2-(benzyloxycarbonylamino)propionique, qui sont utiles en tant qu'antagonistes des récepteurs de l'intégrine .alpha.¿v?.beta.¿3? et de récepteurs de protéines adhésives de surface cellulaire associées, compositions pharmaceutiques contenant lesdits composés, procédés de préparation desdits composés et procédés d'utilisation desdits composés, seuls ou en combinaison avec d'autres agents thérapeutiques pour l'inhibition de l'adhésion cellulaire, le traitement des troubles angiogéniques, des inflammations, de la dégradation osseuse, des métastases cancéreuses, de la rétinopathie diabétique, de la thrombose, de la resténose, de la dégénérescence maculaire et d'autres troubles induits par l'adhésion cellulaire et/ou la migration cellulaire et/ou l'angiogenèse.

Affiliated with

Also associated with

Rating

Novel integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel integrin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1775989